Medicines Co Files 8K - Director, Officer or Compensation Filing >MDCO
Medicines Co Files 8K - Director, Officer or Compensation Filing >MDCO
DJ Medicines Co Files 8K - Director, Officer or Compensation Filing >MDCO
DJ Medicines Co Files 8K-董事，官員或薪酬申請>MDCO
Medicines Co. (MDCO) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S Securities and Exchange Commission on March 12, 2019.
2019年3月12日，董事公司向美國證券交易委員會提交了一份8K表格--微博高管或薪酬申請。
On March 15, 2019, The Medicines Company (the "Company") and Christopher Cox, executive vice president and chief corporate development of the Company, entered into a separation agreement and release (the "Separation Agreement"). Pursuant to the Separation Agreement, Mr. Cox's employment with the Company terminated on March 15, 2019 (the "Termination Date"). Pursuant to the terms of the Separation Agreement, Mr. Cox will be entitled to the following severance benefits: (i) for a period of twelve (12) months after the Termination Date, reimbursement of COBRA health care premiums actually paid by Mr. Cox; (ii) accelerated vesting of all outstanding equity awards previously granted to Mr. Cox and outstanding immediately prior to the Termination Date that would have vested within eighteen (18) months after the Termination Date (assuming Mr. Cox had continued to be employed by the Company during such 18-month period); and (iii) an extended period to exercise vested options for a period of twelve (12) months after the Termination Date. The severance benefits are conditioned upon Mr. Cox not revoking a release of claims in favor of the Company and continuing compliance with his non- solicitation and nondisclosure obligations. In addition, Mr. Cox has agreed that he will hold all equity of the Company for at least twelve (12) months from the Termination Date, subject to certain permitted exceptions.
2019年3月15日，醫藥公司(以下簡稱《本公司》)與執行副總裁、本公司公司發展主管克里斯托弗·考克斯訂立分居協議並解除(《分居協議》)。根據離職協議，考克斯先生於2019年3月15日(“終止日期”)終止受僱於本公司。根據分居協議的條款，考克斯先生將有權獲得以下遣散費福利：(I)在終止日期後十二(12)個月內，償還考克斯先生實際支付的眼鏡蛇醫療保費；(Ii)加速轉歸所有先前授予考克斯先生且在終止日期之前尚未支付的、本應在終止日期後十八(18)個月內歸屬的股權獎勵(假設考克斯先生在該18個月期間繼續受僱於本公司)；以及(Iii)在終止日期後十二(12)個月內行使既得期權的延長期限。遣散費福利的條件是考克斯先生不撤銷對公司有利的索賠釋放，並繼續遵守他的非徵求和保密義務。此外，考克斯先生已同意，他將自終止日期起至少十二(12)個月內持有本公司的全部股權，但某些許可的例外情況除外。
The foregoing is a summary description of the Separation Agreement and does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company's next quarterly report on Form 10-Q after the Separation Agreement becomes irrevocable. Interested parties should read that document in its entirety.
以上為離職協議的概要描述，並不聲稱是完整的，須受離職協議全文的規限，並受該協議全文的規限，而該協議的副本將於離職協議不可撤銷後提交本公司的下一份10-Q表格季度報告作為證物。感興趣的各方應完整閲讀該文件。
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1113481/000111348119000011/mdco8-kcox.htm
這份美國證券交易委員會申報文件的全文可在以下網站檢索：http://www.sec.gov/Archives/edgar/data/1113481/000111348119000011/mdco8-kcox.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: https://www.sec.gov/Archives/edgar/data/1113481/000111348119000011/0001113481-19-000011-index.htm
任何與這份美國證券交易委員會備案相關的展品和相關文件都可以在以下網站檢索：https://www.sec.gov/Archives/edgar/data/1113481/000111348119000011/0001113481-19-000011-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
上市公司必須在任何可能對公司財務狀況或股票價值產生重大影響的事件發生後四天內，向美國證券交易委員會提交一份當前報告。
(END) Dow Jones Newswires
(完)道瓊斯通訊社
March 18, 2019 16:52 ET (20:52 GMT)
2019年3月18日東部時間16：52(格林尼治標準時間20：52)
Copyright (c) 2019 Dow Jones & Company, Inc.
版權所有(C)2019道瓊斯公司。
譯文內容由第三人軟體翻譯。
